The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Activity of new agents (NAs) as third-line treatment in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) after a long-term disease control (LTDC) with abiraterone acetate (AA) or enzalutamide (ENZ) post docetaxel (DOC): Preliminary results from a multicenter Italian study.
 
Antonello Veccia
No Relationships to Disclose
 
Ugo De Giorgi
No Relationships to Disclose
 
Gaetano Facchini
No Relationships to Disclose
 
Lucia Fratino
No Relationships to Disclose
 
Donatello Gasparro
No Relationships to Disclose
 
Daniele Alesini
No Relationships to Disclose
 
Umberto Basso
Honoraria - Sanofi
 
Marcello Tucci
Consulting or Advisory Role - Astellas Pharma; Bayer; Janssen
 
Cinzia Ortega
Consulting or Advisory Role - Astellas Pharma
 
Sarah Scagliarini
No Relationships to Disclose
 
Francesco Verderame
No Relationships to Disclose
 
Giovanni Lo Re
No Relationships to Disclose
 
Giuseppe Procopio
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; GlaxoSmithKline; Janssen; Novartis; Pfizer
 
Roberto Sabbatini
No Relationships to Disclose
 
Enrico Campadelli
No Relationships to Disclose
 
Paolo Andrea Zucali
No Relationships to Disclose
 
Franco Morelli
No Relationships to Disclose
 
Donata Sartori
No Relationships to Disclose
 
Vincenza Conteduca
No Relationships to Disclose
 
Orazio Caffo
Honoraria - Astellas Pharma; Janssen Oncology; Sanofi